Menu
Recruiting NCT06637436

PrEP Readiness Interventions for Sustained Motivation (PRISM)

No phase Interventional HIV Methamphetamine Disorders

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Motivational Interviewing (MI), Contingency Management (CM).
Who it may be relevant to
Registry conditions: HIV, Methamphetamine Disorders. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Optimizing HIV Prevention for Highly Vulnerable Methamphetamine-using Sexual Minority Men

Overview

This is a hybrid type I randomized controlled trial to test the effectiveness of contingency management (CM) alone versus CM with motivational interviewing (MI) for optimizing entry or re-entry into the HIV prevention or care continua. A total of 400 participants will be randomized to CM (n = 200) or MI+CM (n = 200), all delivered via telehealth. Monthly follow-up assessments will be completed over 12 months to examine effectiveness MI+CM for the primary outcome - filling a pre-exposure prophylaxis (PrEP) or anti-retroviral therapy (ART) prescription (verified using a digital photo). Secondary outcomes will include: self-reported PrEP or ART clinical evaluation by a provider; self-reported meth and other substance use severity (ASSIST), and self-reported receptive and insertive condomless anal sex (CAS).

Interventions

  • Behavioral Motivational Interviewing (MI)
    This telehealth MI intervention seeks to increase intrinsic motivation and self-efficacy for starting or restarting PrEP in session one. Session two focuses on concomitant risk behaviors such as substance use and CAS.
  • Behavioral Contingency Management (CM)
    Provides incentives for initiating PrEP or HIV care ($50) and filling a PrEP or ART prescription ($50) in the three months following randomization.

Primary outcome measures

  • Proportion of Participants with Verified PrEP or ART Use [Time frame: 12 Months]
Secondary outcome measures (5)
  • Median Time to Verified PrEP or ART Use [Time frame: 12 Months]
  • Clinical Cut Points for Self-Reported Methamphetamine Use Severity [Time frame: 12 Months]
  • Proportion of Participants Reporting Insertive Condomless Anal Sex (CAS) [Time frame: 12 Months]
  • Proportion of Participants Reporting Receptive Condomless Anal Sex (CAS) [Time frame: 12 Months]
  • Proportion of Participants with Prevention Effective PrEP or ART Use [Time frame: 12 Months]

Eligibility criteria

Inclusion criteria

  • 18 years or older
  • Assigned male a birth
  • Self-reported methamphetamine use in the past 3 months
  • HIV-negative or unknown serostatus at baseline
  • Has not filled a PrEP prescription in the past 6 months

Exclusion criteria

  • Unwilling or unable to provide informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Prevention

Study locations

United States · 1 center
  • Florida International University — Miami

Identifiers

NCT: NCT06637436 · UH3AI169652

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗